Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International Phase IIIb study of every-other-day subcutaneous Betaseron/Betaferon in relapsing multiple sclerosis after BEYOND
2006-005270-47Phase 3Completed
- Sponsor
- Schering AG
- Start
- Dec 2006
- Modality
- Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of interferon beta in multiple sclerosis (MS) (4 arms), sponsored by Schering AG. Primary endpoint: Frequencies of safety and tolerability events at 500 µg IFNB-1b. Started Dec 2006; status: completed.
02
Drugs
interferon beta
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-005270-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005270-47.